Global Carotid Artery Stent Market to Grow Substantially at a CAGR of ~3% by 2030

The rising occurrence of cardiovascular conditions like stroke, ischemic stroke, and transient ischemic attack, among other factors, is driving the demand for carotid artery stents. Moreover, the growing preference for minimally invasive surgical techniques is also playing a significant role in propelling the carotid artery stent market growth

DelveInsight’s Carotid Artery Stent Market Insights report provides the current and forecast market analysis, individual leading carotid artery stent companies’ market shares, challenges, carotid artery stent market drivers, barriers, trends, and key market carotid artery stent companies in the market.

Key Takeaways from the Carotid Artery Stent Market Report

  • As per DelveInsight estimates, North America is anticipated to dominate the global carotid artery stent market during the forecast period.
  • In the product type segment of the carotid artery stents market, the self-expanding stents category had a significant revenue share in the year 2023. This can be attributed to the various applications and advantages associated with the self-expanding stents such as self-expanding stents adapt to the anatomy of the carotid area.
  • Notable carotid artery stent companies such as Boston Scientific Corporation, Cordis, Balton, Medtronic, Terumo Europe NV, Silk Road Medical Inc., InspireMD Inc., and several others, are currently operating in the carotid artery stent market.
  • In October 2023, Boston Scientific Corporation got approval for its Carotid WALLSTENT® Monorail® from USFDA for the treatment of carotid artery disease.
  • In October 2022, Cordis a leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, acquired MedAlliance.

To read more about the latest highlights related to the carotid artery stent market, get a snapshot of the key highlights entailed in the Global Carotid Artery Stent Market Report

Carotid Artery Stent Overview

Carotid artery stenting is a minimally invasive procedure used to treat carotid artery disease, a condition where the carotid arteries, located in the neck, become narrowed or blocked by the buildup of plaque. During the procedure, a slender tube called a catheter is inserted into an artery, usually in the groin, and guided to the carotid artery under X-ray imaging. Once in place, a stent—a small mesh tube—is expanded within the narrowed portion of the artery, pushing aside the plaque and restoring blood flow to the brain. This technique is an alternative to carotid endarterectomy, a surgical procedure that involves opening the carotid artery and removing the plaque.

While carotid artery stenting is less invasive compared to surgery, it’s not without risks. Complications can include stroke, bleeding at the puncture site, or the formation of blood clots. However, for certain patients, such as those deemed high-risk for surgery due to other health conditions, or those with difficult-to-reach blockages, carotid artery stenting can be a valuable treatment option. It offers a shorter recovery time and avoids the need for general anesthesia, making it a preferred choice for some individuals. Close monitoring and careful patient selection are crucial to ensure the best possible outcomes.

Carotid Artery Stent Market Insights

In 2023, North America dominated the carotid artery stents market, mainly due to the increasing incidence of cardiovascular diseases and associated risk factors like obesity, hypertension, and diabetes. Factors like government initiatives, high disposable income, a growing aging population, and advanced healthcare facilities further drive market growth in the region.

According to the Centers for Disease Control and Prevention (CDC) in 2022, around 18.2 million adults in the US suffer from coronary artery disease, with approximately 805,000 experiencing heart attacks annually, a significant portion being first-time occurrences. Moreover, the elderly population, especially those over 50, are particularly susceptible to carotid artery disease due to age-related arterial changes.

The United States Census Bureau’s 2021 report indicates that over 54 million adults aged 65 and older lived in the US, and this demographic is expected to reach 85.7 million by 2050, constituting about 20% of the total population. This aging population contributes to the rising demand for carotid artery stents.

Furthermore, the presence of major industry players like Boston Scientific Corporation, Cordis, and Silk Road Medical Inc. headquartered in North America also bolsters the carotid artery stent market growth in the region. Consequently, the increasing prevalence of cardiovascular diseases and the concentration of key market players are driving the expansion of the carotid artery stent market in North America.

To know more about why North America is leading the market growth in the carotid artery stent market, get a snapshot of the Carotid Artery Stent Market Outlook 

Carotid Artery Stent Market Dynamics

The carotid artery stent market has seen significant dynamics over the past few years, driven by a combination of technological advancements, evolving healthcare policies, and increasing prevalence of carotid artery diseases. Carotid artery stenting has emerged as a minimally invasive alternative to traditional surgical interventions for treating carotid artery stenosis, offering reduced recovery times and fewer complications for patients. As a result, the demand for carotid artery stents has been steadily increasing, particularly among aging populations where vascular diseases are more prevalent.

One of the key drivers shaping the carotid artery stent market dynamics is the growing adoption of endovascular procedures by healthcare providers. With advancements in stent design, materials, and delivery systems, carotid artery stenting has become safer and more effective, leading to its wider acceptance as a treatment option. Moreover, the rise in awareness campaigns about stroke prevention and early detection of carotid artery diseases has further fueled the demand for stenting procedures.

However, despite these advancements, challenges persist in the carotid artery stent market. Issues such as stent thrombosis, restenosis, and embolization remain concerns, necessitating ongoing research and development efforts to improve stent design and minimize complications. Additionally, regulatory hurdles and reimbursement policies can impact carotid artery stent market growth, influencing the adoption rates of carotid artery stenting procedures in different regions.

Looking ahead, the carotid artery stent market is poised for continued growth, driven by factors such as an aging population, increasing prevalence of vascular diseases, and ongoing innovations in stent technology. With a focus on improving patient outcomes and reducing procedural risks, manufacturers and healthcare providers are likely to invest further in research, development, and training initiatives to expand the accessibility and efficacy of carotid artery stenting procedures.

Get a sneak peek at the carotid artery stent market dynamics @ Carotid Artery Stent Market Dynamics Analysis

Report Metrics

Details

Coverage

Global

Study Period

2021–2030

Carotid Artery Stent Market CAGR

~3%

Carotid Artery Stent Market Size by 2030

USD 718.25 Million

Key Carotid Artery Stent Companies

Boston Scientific Corporation, Cordis, Balton, Medtronic, Terumo Europe NV, Silk Road Medical Inc., InspireMD Inc., among others

Carotid Artery Stent Market Assessment

  • Carotid Artery Stent Market Segmentation
    • Carotid Artery Stent Market Segmentation By Product Type: Self-Expanding Stents, Balloon Expandable Stents, and Others
    • Carotid Artery Stent Market Segmentation By End User: Hospitals & Clinics, Ambulatory Surgical Centers, and Cardiac Centers
    • Carotid Artery Stent Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the carotid artery stent market are set to emerge as the trendsetter explore @ Carotid Artery Stent Companies

Table of Contents 

1

Report Introduction

2

Executive summary

3

Regulatory and Patent Analysis

4

Key Factors Analysis

5

Porter’s Five Forces Analysis

6

Carotid Artery Stent Market Layout

7

Global Company Share Analysis – Key 3-5 Companies

8

Carotid Artery Stent Market Company and Product Profiles

9

Project Approach

10

About DelveInsight

Interested in knowing the carotid artery stent market by 2030? Click to get a snapshot of the Carotid Artery Stent Market Trends

Related Reports

Ischemic Stroke Pipeline

Ischemic Stroke Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ischemic Stroke companies, including Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz, among others.

Ischemic Stroke Epidemiology

Ischemic Stroke Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted ischemic stroke epidemiology in the 7MM.

Acute Ischemic Stroke Market

Acute Ischemic Stroke Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute ischemic stroke companies, including Acticor Biotech, DiaMedica Therapeutics, Lumosa Therapeutics, Bristol Myers Squibb, Janssen Pharmaceutical, Genentech, Inc., Athersy, Healios K.K., NoNO Inc., Bayer, ZZ Biotech, Biogen Inc., Revalesio Corporation, AbbVie, TrueBinding, Inc, Silver Creek Pharmaceuticals, among others.

Acute Ischemic Stroke Pipeline

Acute Ischemic Stroke Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute ischemic stroke companies, including Genentech, Acticor Biotech, DiaMedica Therapeutics, and NoNO, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”